In Brief: J&J/Merck's Mylanta AR
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck's Mylanta AR: Will enter the H2 antagonist market in January, Merck Senior VP and Chief Financial Officer Judy Lewent said at a Dec. 18 securities analysts meeting in Whitehouse Station, N.J. The product will contain 10 mg famotidine, the active ingredient in J&J/Merck's Pepcid AC. According to the company, in-house research shows that 50% of consumers who suffer from heartburn have not tried an acid blocking product, preferring to stick to more familiar remedies. J&J/Merck hopes the well-known Mylanta name will help lure these cautious consumers into the new category...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning